Reference : From "an enzyme able to destroy penicillin" to Carbapenemases: 70 Years of Beta-lacta...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
Life sciences : Microbiology
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/2268/186609
From "an enzyme able to destroy penicillin" to Carbapenemases: 70 Years of Beta-lactamase Misbehaviour
English
Frère, Jean-Marie mailto [Université de Liège > > Centre d'ingénierie des protéines >]
Sauvage, Eric mailto [Université de Liège > > Centre d'ingénierie des protéines >]
Kerff, Frederic [Université de Liège - ULiège > > >]
2016
Current Drug Targets
Yes (verified by ORBi)
International
1389-4501
1873-5592
[en] As early as 1940, Abraham and Chain described "an enzyme able to destroy penicillin". In the late 1940's, penicillin-resistant strains of Staphylococcus aureus were found to be a clinical problem. They produced a penicillinase that could hydrolyze the amide bond in the beta-lactam ring. Later, an enzyme mediated by an R-factor was isolated from Enterobacteriaceae. Methicillin and cephalosporins, both very poor substrates of the S. aureus enzyme, were found to be sensitive to this new enzyme. Third generation cephalosporins appeared to solve the problem, but further enzymes were selected that exhibited extended spectra and could for instance hydrolyze cefotaxime and/or ceftazidime. The discovery of carbapenems constituted a major advance for our antimicrobial arsenal: they inactivated most of the essential penicillin binding proteins effectively and escaped the activity of nearly all known beta-lactamases. However, the metallo-beta-lactamases, which had not been recognised as a major danger before 1990, were found to act as effective carbapenemases and started to spread in a worrying way. Moreover, carbapenem-hydrolyzing enzymes were found in each of the 3 classes of active-site serine beta-lactamases.
http://hdl.handle.net/2268/186609
10.2174/1389450116666151001112859

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
2015_CurrDrugTarget-carbapenemases.pdfAuthor preprint6.08 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.